Pharmacogenomics (PGx) for Depression: Genetic Analysis to Amplify Antidepressant Efficacy? (2023 Review)
Depression, a leading cause of disability globally, often presents challenges in treatment due to the variability in individual responses to antidepressants. Pharmacogenomic (PGx) testing, an approach aligning treatment with genetic makeup, promises to tailor depression therapy more effectively. Highlights: Major Depressive Disorder (MDD) impacts a significant portion of the global population, with traditional treatments often …